New crown vaccine inoculation exceeds 100 million, Sinopharm designs vaccine to strengthen injection to improve antibody persistence

At a press conference held by the Joint Prevention and Control Mechanism of the State Council, Zhang Yuntao, vice president of Sinopharm China Biotechnology, said that from the preliminary results obtained, the booster injection of the new crown vaccine can effectively improve the durability of antibodies and improve the ability of the vaccine to resist mutation.

At the same time, Zhang Yuntao also said that in the future, Sinopharm’s enhanced needle will carry out Phase III clinical studies overseas and continue to observe to see the durability of its protection.

As of March 27, 2021, my country has reported more than 100 million doses of new coronavirus vaccines.

However, although the protection effectiveness data published by the domestically-made new crown vaccines currently approved for conditional marketing have all reached the relevant technical standards of the World Health Organization and relevant national technical standards, the validity period of the vaccine is still difficult to maintain for a long time.

In this regard, Wang Huaqing, chief expert of the China Centers for Disease Control and Prevention's immunization program, said that the relatively long-term vaccines have been observed and studied to assess how long their effective protection period is.

Therefore, in order to improve the effective period of the vaccine after the inoculation of the human body, Zhang Yuntao said that Sinopharm has designed the booster vaccination in the clinical process of the overall design.

In addition, regarding the performance of Sinopharm’s new crown vaccine booster injection and specific vaccination time and other related issues, Zhang Yuntao said that in the next phase, Sinopharm’s enhancement injection research and development will carry out phase three clinical studies overseas to continue to observe antibody durability and protection.